ResearchAndMarkets adds clinical-stage partnering deals 2020-2026 report
The publication reviews more than 1,859 clinical-stage pharmaceutical and biotechnology partnering deals, including disclosed upfronts, milestones and other financial terms.
ResearchAndMarkets.com has added a report covering more than 1,859 clinical-stage partnering deals in pharmaceuticals and biotechnology from 2020 to 2026. The publication examines how clinical-stage transactions are structured across the sector, with a focus on disclosed financial terms including upfront payments and milestone payments. Positioned as a dealmaking reference tool, the report is aimed at business development, licensing and strategy professionals seeking to benchmark comparable transactions and assess market practice in late-stage drug development partnerships.
- clinical-stage partnering deals: Agreements involving drug candidates that have entered human testing, often covering licensing, co-development or other collaboration terms.
- milestone payments: Contract payments triggered when a project reaches specified development, regulatory or commercial goals.